Indrayani Biotech Ltd
Incorporated in 1992, Indrayani Biotech
Ltd is in the business of Foods & Hospitality, Engineering and Healthcare[1]
- Market Cap ₹ 34.8 Cr.
- Current Price ₹ 7.65
- High / Low ₹ 23.5 / 6.71
- Stock P/E
- Book Value ₹ 16.6
- Dividend Yield 0.00 %
- ROCE 2.82 %
- ROE -2.23 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.44 times its book value
- Company is expected to give good quarter
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 33.3%
- Company has a low return on equity of 8.61% over last 3 years.
- Earnings include an other income of Rs.6.47 Cr.
- Company has high debtors of 164 days.
- Promoter holding has decreased over last 3 years: -11.6%
- Working capital days have increased from 114 days to 211 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2010 | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 39 | 58 | 50 | 21 | 61 | 163 | 165 | 130 | 151 | |
| 0 | 39 | 57 | 47 | 26 | 54 | 145 | 142 | 124 | 146 | |
| Operating Profit | -0 | 1 | 1 | 3 | -5 | 7 | 17 | 24 | 6 | 5 |
| OPM % | -105% | 2% | 1% | 6% | -24% | 11% | 11% | 14% | 5% | 3% |
| 0 | 0 | 0 | 0 | -4 | 0 | 4 | 1 | 3 | 6 | |
| Interest | 0 | 0 | 0 | 1 | 2 | 2 | 6 | 10 | 12 | 5 |
| Depreciation | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 4 | 3 | 13 |
| Profit before tax | -0 | 0 | 0 | 1 | -11 | 4 | 12 | 11 | -6 | -7 |
| Tax % | 0% | 150% | 300% | 0% | 0% | 0% | 3% | 5% | 6% | |
| -0 | -0 | -0 | 1 | -11 | 4 | 12 | 10 | -6 | -7 | |
| EPS in Rs | -0.14 | -0.16 | 2.22 | -3.28 | 1.30 | 2.55 | 1.40 | -0.34 | -1.73 | |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 29% |
| TTM: | 21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -228% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 1% |
| 3 Years: | -52% |
| 1 Year: | -66% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | 9% |
| Last Year: | -2% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2010 | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 4 | 4 | 4 | 34 | 34 | 34 | 46 | 46 | 46 |
| Reserves | -6 | -0 | -0 | 27 | -15 | -10 | 12 | 22 | 27 | 30 |
| 0 | 0 | 0 | 14 | 16 | 19 | 79 | 113 | 137 | 146 | |
| 1 | 6 | 9 | 7 | 5 | 8 | 31 | 54 | 59 | 52 | |
| Total Liabilities | 1 | 10 | 12 | 51 | 40 | 51 | 156 | 234 | 268 | 274 |
| 1 | 6 | 6 | 17 | 15 | 17 | 57 | 62 | 58 | 62 | |
| CWIP | -0 | 0 | 0 | 14 | 14 | 13 | 14 | 20 | 26 | 23 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 4 | 7 | 21 | 11 | 22 | 85 | 151 | 185 | 189 | |
| Total Assets | 1 | 10 | 12 | 51 | 40 | 51 | 156 | 234 | 268 | 274 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2010 | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 6 | 0 | 4 | 16 | -30 | -7 | ||
| -3 | -0 | -4 | -1 | -1 | -47 | -16 | 25 | ||
| 2 | -1 | -1 | -0 | -3 | 33 | 44 | -18 | ||
| Net Cash Flow | 0 | 1 | 1 | -1 | 1 | 2 | -2 | -0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2010 | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0 | 26 | 26 | 52 | 84 | 84 | 67 | 87 | 164 |
| Inventory Days | 365 | 57 | 25 | 14 | 44 | 159 | 182 | ||
| Days Payable | 365 | 70 | 77 | 52 | 81 | 141 | 104 | ||
| Cash Conversion Cycle | 0 | 26 | 26 | 38 | 32 | 46 | 30 | 106 | 243 |
| Working Capital Days | -1,883 | -22 | -19 | 30 | -59 | -12 | 6 | 127 | 211 |
| ROCE % | 28% | 12% | -13% | 16% | 23% | 14% | 3% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Permanent Employee Count Employees |
|
|||||||||
| Daily Meal Production Capacity (A-Diet) Meals per day |
||||||||||
| Number of States of Operation (A-Diet) States |
||||||||||
| Farming Land Area Acres |
||||||||||
| Industrial Boiler Manufacturing Capacity TPH |
||||||||||
| Milk Procurement Volume (Dindigul Farm) Liters per day |
||||||||||
| Milk Processing Capacity (Group) Liters per day |
||||||||||
| Healthway / Pharma Retail Outlets Outlets |
||||||||||
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
28 Feb - Newspaper Publication for the unaudited financial results (Standalone and consolidated) for the Quarter ended December 31, 2025
- Results - Unaudited Financial Results For Quarter Ended December 2025 26 Feb
-
Announcement under Regulation 30 (LODR)-Change in Management
26 Feb - Approved Q3 results (Dec 31, 2025); CFO resigned 26 Feb; new CFO 27 Feb; Rs5 Cr loan; expedite rights issue.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 26Th February, 2026
26 Feb - Approved Q3 results; CFO resigned 26-Feb-2026, new CFO appointed 27-Feb-2026; Rs5 Crore credit; rights issue expedited.
-
Board Meeting Intimation for Intimation For Board Meeting To Be Held On 26Th February, 2026
23 Feb - Board meeting Feb 26, 2026 to approve unaudited Q3 results ended Dec 31, 2025; trading window closed from Jan 1.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
IBL has multiple business units managed by an
independent team of field experts. It operates
in Food and Hospitality, Dairy, Healthcare & Pharma, Engineering, Biotech, Agriculture and Infrastructure